Gestational Diabetes Mellitus and Cardiometabolic Syndrome in Offspring

Is Gestational Diabetes Mellitus (GDM) an Independent Risk Factor for Cardiometabolic Syndrome in Offspring?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01490372

Acronym

DG3

Enrollment

Registered

2011-12-13

Start date

2011-08-31

Completion date

2013-05-31

Last updated

2018-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes Mellitus

Brief summary

Gestational Diabetes Mellitus (GDM) has long been known as leading to macrosomias, neonatal hypoglycemias and other complications which are treatable and preventable. Nowadays, GDM is recognized as an entity with long-term serious sequels to the mother (GDM is considered a forerunner of type 2 diabetes) and her offspring. Indeed, according to the programming hypothesis, GDM sets the stage for metabolic syndrome, obesity, type 2 diabetes and hypertension. However, these cross-sectional studies failed to control for maternal disease history and genetic background although heredity is a major epidemiology risk factor of type 2 diabetes. Also, studies usually refer to traditional markers such as BMI, blood pressure, lipids profile and oral glucose tolerance test (OGTT); none explored inflammatory biomarkers and adipokines in-depth, despite the possible link between their presence and the development of metabolic and cardiovascular diseases in GDM offsprings. Exclusion of genetic confounding factors will help establish the role of GDM as an independent marker of cardiometabolic risk in GDM offspring. It is highly relevant to identify GDM as a risk factor for cardiometabolic diseases, given the worldwide obesity epidemic, the alarming prevalence increase of GDM and its serious sequels to both mother and offspring.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

4 Years to 12 Years

Healthy volunteers

Inclusion criteria

* age 4 to 12 years * Tanner stage \< 2 * to understand French or English

Exclusion criteria

* Type 1 diabetes * weight \< 10 kg * placenta abnormalities * gestational age \< 34 weeks * illness affecting growth and metabolism * taking medications

Design outcomes

Primary

Measure	Time frame	Description
Metabolic syndrome	4 to 12 years after birth.	Prevalence of metabolic syndrome

Secondary

Measure	Time frame	Description
Inflammatory markers	Assessed only once 4 to 12 years after birth	4 to 12 years after birth.

Countries

Canada

Outcome results